Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 3000 in its research report dated August 02, ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Tesla awarded CEO Elon Musk 96 million shares of restricted stock valued at approximately $29 billion, six months after a ...

Prabhudas Lilladher recommended Accumulate rating on Tata Steel with a target price of Rs 177 in its research report dated ...

Biotech bigwig Gilead Sciences, Inc. (GILD) is scheduled to report second-quarter 2025 results on Aug. 7, after market close.

To lift productivity and growth, Australia must embrace risk, innovation and accountability, from startups to the boardrooms ...